Drug Trial Radar · NCT03961568
Cenobamate Open-Label Extension Study for YKP3089C025
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Aug 13, 2019
Primary completion
Jun 10, 2026
Study completion Jun 10, 2026
Sponsor
- Lead sponsor
- SK Life Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)
Conditions
- Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Interventions
CenobamateDrug
active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events and SAEsTime frame: 386 +/- 2 days
Locations
45 sites in 7 countries. Site status is shown where the registry gives one.
University of California, San Diego (UCSD)
La Jolla, California
The Neurology Research Group, LLC.
Miami, Florida
University of South Florida
Tampa, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho
Maine Medical Center
Scarborough, Maine
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
Mayo Clinic - Rochester
Rochester, Minnesota
University of Missouri Medical School
Columbia, Missouri
Northeast Regional Epilepsy Group
Hackensack, New Jersey
Five Towns Neuroscience Research
Woodmere, New York
Duke University
Durham, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Valley Medical Center
Renton, Washington
MultiCare Rockwood Neurology Center
Spokane, Washington
Multiprofile Hospital for Active Treatment Puls AD
Blagoevgrad, Blagoevgrad, Bulgaria
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD
Sofia, Sofia, Bulgaria
Diagnostic Consultative Center Neoclinic EAD
Sofia, Sofia, Bulgaria
Diagnostic Consultative Center Equita EOOD
Varna, Varna, Bulgaria
Medical Center Medica Plus OOD
Veliko Tarnovo, Veliko Tarnovo, Bulgaria
Multiprofile Hospital for Active Treatment Sv. Ivan Rilski Gorna Oryahovitsa EOOD
Veliko Tarnovo, Veliko Tarnovo, Bulgaria
Cerebrovaskularni poradna
Ostrava-Poruba, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Forbeli s.r.o.-Neurologicka ambulance
Prague, Czechia
Neurologicka ambulance
Zlín, Czechia
Semmelweis Egyetem I. Sz. Gyermekgyogyaszati Klinika
Budapest, Hungary
Clinical Research Center Spólka z Ograniczona Odpowiedzialnoscia Medic-R sp. k.
Poznan, Greater Poland Voivodeship, Poland
Centrum Leczenia Padaczki i Migreny
Krakow, Lesser Poland Voivodeship, Poland
Centrum Medyczne Pratia Warszawa
Warsaw, Masovian Voivodeship, Poland
Górnoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, Silesian Voivodeship, Poland
MUDr. Beata Dupejova, neurologicka ambulancia, s.r.o.
Banská Bystrica, Slovakia
IN MEDIC s.r.o.
Bardejov, Slovakia
Konzilium, s.r.o.
Dubnica nad Váhom, Slovakia
Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov", Regional Center
Dnipro, Ukraine
Municipal Institution "Dnipropetrovsk Regional Clinical Hospital named after I. I. Mechnikov"
Dnipro, Ukraine
Regional Psyconeurology Hospital #3
Ivano-Frankivsk, Ukraine
Communal Non-Commercial Enterprise of Kharkiv Regional Council
Kharkiv, Ukraine
Municipal Institution of Lviv Regional Council
Lviv, Ukraine
Ternopil Regional Municipal Psychoneurological Hospital
Ternopil, Ukraine
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.